Nature Medicine's July 2026 AI superintelligence framework exposes a critical gap: FDA has no task-based benchmarking standard for medical...

Oryzon's iadademstat shows 78% CR rate in AML patients with TP53 and RAS mutations, addressing historically treatment-resistant genomic subgroups.

MapLight's ML-007C-MA met its primary endpoint in Phase 2 schizophrenia trial, showing significant PANSS improvement and cognitive benefits with...

87% of clinical trial sites use decentralized elements, yet most still rely on spreadsheets. SaaS platforms are closing that...

A 99,783-person multi-ancestry Parkinson's study just exposed a critical enrollment gap: GBA1 and LRRK2 trials run almost exclusively in...

383 NIH-funded clinical trials terminated, exposing structural pressures on research sites managing funding cuts and protocol complexity simultaneously.

Incyte's STOP-HS1/2 trials (1,227 patients) show how JAK1-selective design and rigorous RCT methodology are reshaping dermatology's clinical trial landscape.

argenx acquires Forte Biosciences for $2.2 billion to gain FB102 antibody, an anti-CD122 treatment showing Phase 1b efficacy in...

WCG CenterWatch 2025 Report reveals where AI adoption stands in clinical research, showing implementation gaps between aspiration and execution.

92% of clinical trial organizations plan AI investment within two years, though only one-third currently use it meaningfully across...